Digital diagnostics company Paige announces its plans to deploy a one-of-a-kind artificial intelligence (AI)-powered biomarker test for advanced bladder cancer in clinical settings.
Paige is collaborating with Janssen Research & Development to carry out this project. Janssen Research & Development will assess the ability of a hematoxylin and eosin (H&E)-based, AI-powered biomarker test to predict the presence of specific, actionable alterations in the fibroblast growth factor receptor (FGFR) genes in patients with advanced urothelial cancer.
The tests will be conducted on patients with advanced urothelial cancer, also known as bladder cancer. The test is the world’s most unique test in terms of predicting the presence of actionable genetic changes. Paige’s Platform is now being used in clinical trials by Janssen to screen for FGFR gene changes in adult patients with advanced urothelial carcinoma.
President and Chief Business Officer at Paige, Jill Stefanelli, said, “We are excited to mark a new chapter in deploying Janssen’s AI technology in a clinical setting to efficiently detect biomarkers, in this case, some rare gene mutations and fusions.”
Jill further added that they will make its capabilities broadly accessible in support of the clinical development of targeted and other kinds of therapeutic medications, along with patient identification for future biomarker and drug development initiatives, now that their Paige Platform has been deployed globally.
United States-based leading digital diagnostics company Paige was founded by David Klimstra, Norman Selby, Peter Schüffler, and Thomas Fuchs in 2018. Paige specializes in building computational pathology tools that help patients and their care teams make better-educated treatment decisions. The company’s light platform was designed with pathologists in mind to provide a simple user experience, reduce IT strain and expenses, and ensure patient safety and data protection.